Matches in Nanopublications for { ?s ?p "[We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP740389.RAZU_V8b8UpcqOYzT3rKFLrt3zi0dFOCkvdb5DdVNl1Ws130_assertion description "[We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP740389.RAZU_V8b8UpcqOYzT3rKFLrt3zi0dFOCkvdb5DdVNl1Ws130_provenance.
- NP740393.RAdzn1qpxTQyGQYruyNOpE2gATWZ7Hb5HiuSP53On_mQs130_assertion description "[We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP740393.RAdzn1qpxTQyGQYruyNOpE2gATWZ7Hb5HiuSP53On_mQs130_provenance.
- NP740391.RAlkQ4irILG8V6HtkieuVOEFFFmXu9H_4bdtG41I_46qU130_assertion description "[We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP740391.RAlkQ4irILG8V6HtkieuVOEFFFmXu9H_4bdtG41I_46qU130_provenance.
- NP740392.RArPPNCW6-aNO21oKsVDdRqxf_Ji-9jXMSpUE0yVdz2LA130_assertion description "[We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP740392.RArPPNCW6-aNO21oKsVDdRqxf_Ji-9jXMSpUE0yVdz2LA130_provenance.